显色原位杂交与免疫组织化学检测乳腺癌HER-2基因的比较研究  

Comparision of HER-2 Oncogene Detected by Chromogenic in Situ Hybridization and Immunohistochemistry in Breast Cancer

作　　者：秦璟[1] 马爱玲[1] 

机构地区：[1]宁夏医学院附属医院病理科,银川750004

出　　处：《宁夏医学院学报》2008年第6期700-702,F0004,共4页Journal of Ningxia Medical College

摘　　要：目的探讨显色原位杂交(CISH)在检测乳腺癌组织中HER-2基因扩增的作用,比较CISH与免疫组化(IHC)检测组织HER-2状态的差异性。方法采用SPOT-Light HER2 CISHTM试剂盒,以CISH方法对40例IHC EnVision法染色分别为(+++)、(++)、(+)的乳腺癌石蜡切片标本进行HER-2基因状态的检测。结果在15例经IHC检测HER-2水平表达为(+++)乳腺癌标本中14例为HER-2基因高扩增,1例无扩增;16例经IHC检测HER-2水平表达为(++)乳腺癌标本中,11例为HER-2基因高扩增,5例无扩增;9例经IHC检测为(+)的标本均无扩增。两种方法对乳腺癌组织HER-2状态的检测有一定的差异性(P<0.05)。结论IHC是HER-2表达初步筛查的首选方法,由于蛋白表达和基因扩增检测结果存在一定的差异性,建议IHC(+^+++)患者进一步作CISH检测确诊。Objective To explore the effect of CISH on detecting gene amplification of HER-2 in breast cancer and to compare the results with those obtained by immunohistochemistry（IHC）. Methods CISH for HER-2 gene expression was performed using SPOT-Light HER2 CISHTM on the archival paraffin-embedded sections of breast cancer tissues from 40cases with immunohistochemical staining scores of （ ＋ ＋ ＋ ）, （ ＋ ＋ ）, （ ＋ ）. Results Of the 15 cases with score （ ＋ ＋ ＋ ） by IHC, 14 cases showed HER-2 gene amplification by CISH, 1 case CISH-negative. 11 of the 16 cases with score （ ＋ ＋ ） showed HER-2 gene amplification, the remaining 5 cases were CISH-nega- tive. 9 cases with score （ ＋ ） were CISH-negative. Certain difference to the examination of HER-2 was found in the two kinds of method （P 〈 0.05）. Conclusion Immunohistochemistry（IHC） is the first choice in primary screening for HER-2 expression status. Because of the obvious discrepancies between protein expression and gene amplification, patients with score （ ＋ - ＋ ＋ ＋ ） by IHC should undergo CISH testing.

关 键 词：显色原位杂交 免疫组化 乳腺癌 基因 HER-2 

分 类 号：R737.9[医药卫生—肿瘤]